Related Experiment Video
Updated: Apr 21, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model
Izabela Mlynarczuk-Bialy1, Thorsten R Doeppner2, Jakub Golab3
1Department of Histology and Embryology, Warsaw Medical University, Warsaw, Poland.
Abstract:
Inhibition of the proteasome offers many therapeutic possibilities in inflammation as well as in neoplastic diseases. However, clinical use of proteasome inhibitors is limited by the development of resistance or severe side effects. In our study we characterized the anti-tumor properties of the novel proteasome inhibitor BSc2118. The sensitivity of tumor lines to BSc2118 was analyzed in comparison to bortezomib using crystal violet staining in order to assess cell viability. The In Vivo distribution of BSc2118 in mouse tissues was tracked by a fluorescent-modified form of BSc2118 (BSc2118-FL) and visualized by confocal microscopy. Inhibition of the 20S proteasome was monitored both in cultured cell lines and in mice, respectively. Finally, safety and efficacy of BSc2118 was evaluated in a mouse melanoma model. BSc2118 inhibits proliferation of different tumor cell lines with a similar potency as compared with bortezomib. Systemic administration of BSc2118 in mice is well tolerated, even when given in a dose of 60 mg/kg body weight. After systemic injection of BSc2118 or bortezomib similar proteasome inhibition patterns are observed within the murine organs. Detection of BSc2118-FL revealed correlation of distribution pattern of BSc2118 with inhibition of proteasomal activity in cells or mouse tissues. Finally, administration of BSc2118 in a mouse melanoma model shows significant local anti-tumor effects. Concluding, BSc2118 represents a novel low-toxic agent that might be alternatively used for known proteasome inhibitors in anti-cancer treatment.
Insights
A novel proteasome inhibitor, BSc2118, demonstrates potent anti-tumor properties comparable to bortezomib. This low-toxicity agent shows significant efficacy in a mouse melanoma model, offering a potential alternative for cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Proteasome inhibitors offer therapeutic potential for cancer and inflammatory diseases.
- Clinical application of current proteasome inhibitors is hindered by resistance and side effects.
Purpose of the Study:
- To characterize the anti-tumor properties and safety of a novel proteasome inhibitor, BSc2118.
- To compare BSc2118 with bortezomib in terms of efficacy, distribution, and proteasome inhibition.
Main Methods:
- Cell viability was assessed using crystal violet staining to compare BSc2118 and bortezomib sensitivity.
- In vivo distribution of a fluorescently tagged BSc2118 (BSc2118-FL) was visualized using confocal microscopy.
- 20S proteasome inhibition was monitored in cell lines and mice; safety and efficacy were evaluated in a mouse melanoma model.
Main Results:
- BSc2118 exhibited similar anti-proliferative potency against tumor cell lines as bortezomib.
- Systemic administration of BSc2118 was well-tolerated in mice, even at high doses.
- BSc2118 showed comparable proteasome inhibition patterns to bortezomib in murine organs, with distribution correlating to activity.
- BSc2118 demonstrated significant local anti-tumor effects in a mouse melanoma model.
Conclusions:
- BSc2118 is a novel proteasome inhibitor with potent anti-tumor activity and a favorable safety profile.
- BSc2118 may serve as a valuable alternative to existing proteasome inhibitors in anti-cancer therapy.
